Global Antiretroviral Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

November 2017 | 224 pages | ID: G4B4DDE645DEN
Precision Business Insights (PBI)

Abstracts

Antiretroviral Drugs Market

Retroviruses is a single stranded RNA containing virus with DNA intermediate. Retrovirus use enzyme, reverse transcriptase to copy their RNA into DNA of the host cell. The retrovirus integrates its viral DNA into DNA of the host cell, which allows the retrovirus to replicate. Retroviruses can cause different outcomes for the infected cell. Retroviruses are capable of inducing autoimmune, immunosuppressive, and neurological illnesses. Some retroviruses, such as the spumaviruses and lentiviruses are capable of directly killing cells.

Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-Cell leukaemia. Acquired immune deficiency syndrome (AIDS) caused by retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that acts or inhibit certain process in viral replication and inhibits further worsening of the diseases.

Globally antiretroviral drugs market driven by increased cases of retroviral infections such as especially HIV/AIDS. According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS related illness in the same year. The higher prevalence of HIV owing to the various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, increased funding by the government are expected to bolster the antiretroviral drugs market over the forecast period. However, high costs of R&D and stringent regulatory procedures hampering the antiretroviral drugs market. Furthermore, availability of the generic versions of blockbuster drugs affecting the market revenue of antiretroviral drugs.

Global antiretroviral drugs market is segmented based on drug class, route of administration, and distribution channel

Based on drug class, antiretroviral drugs are classified into

• Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
• Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
• Protease Inhibitors
• Integrate Inhibitors
• Fusion Inhibitors
• Chemokine Receptor Inhibitors
• Others

Based on route of administration, antiretroviral drugs are classified into

• Oral
• Parenteral

Based on distribution channel, antiretroviral drugs market is classified into

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Antiretroviral drugs market is expected to grow at significant rates during forecasting period owing to pipeline drugs such as doravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec) etc. Market players are adopting strategies like mergers and acquisitions to improve the market share. In December 2015, ViiV Healthcare purchased Bristol-Myers Squibb’s late stage HIV R&D assets. Market players are also actively collaborating with government and non-government organizations to educate the people and increase awareness related to retroviral diseases. For instance, in September 2016, in an effort to eradicate and combat HIV/AIDS and hypertension in Africa, under U.S. Presidents Emergency Plan for Aids Relief (PEPFAR), United States partnered with AstraZeneca Plc in donating US$10 million to HIV/AIDS funding.

Geographically antiretroviral drugs market is segmented into five key regions Viz. North America, Europe, Asia- Pacific, Latin America, and Middle East & Africa. North America antiretroviral market is driven by introduction of combination therapies such as antiretroviral therapy dosages by key players in the region. Asia Pacific region expected to be fastest growing due to developing healthcare infrastructure and increase in government and non-government organization initiatives creating awareness of retroviral diseases especially HIV/AIDS. Asia Pacific region has many generic drug manufacturing companies that are already have significant presence in global retroviral drugs in market. Middle East and Africa region is expected to be key region owing to availability of large pool of patients with retroviral diseases. However, poor healthcare infrastructure and lack of awareness related to retroviral diseases among healthcare professionals expected to hamper market revenue growth in the region.

Some of the players in the antiretroviral drugs market are Abbott Laboratories (U.S.), AstraZeneca plc (U.K.), Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S), Gilead Sciences (U.S.), GlaxoSmithKline Plc (U.K.), and F. Hoffmann-La Roche AG (Switzerland) to name a few

In November 2016, ViiV Healthcare (Pfizer and GlaxoSmithKline’s joint venture) received U.S. FDA approval to market selzentry for the treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents.

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ANTIRETROVIRAL DRUGS MARKET INTRODUCTION

2.1. Global Antiretroviral Drugs Market – Taxonomy
2.2. Global Antiretroviral Drugs Market –Definitions
  2.2.1. Drug Class
  2.2.2. Route of Administration
  2.2.3. Distribution Channel

3. GLOBAL ANTIRETROVIRAL DRUGS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Antiretroviral Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Antiretroviral Drugs Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Antiretroviral Drugs Market – Product Innovations

4. GLOBAL ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL ANTIRETROVIRAL DRUGS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. Protease Inhibitors
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis
5.4. Integrate Inhibitors
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.4.3. Market Opportunity Analysis
5.5. Fusion Inhibitors
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.5.3. Market Opportunity Analysis
5.6. Chemokine Receptor Inhibitors
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.6.3. Market Opportunity Analysis
5.7. Others
  5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.7.3. Market Opportunity Analysis

6. GLOBAL ANTIRETROVIRAL DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Parenteral
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Oral
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis

7. GLOBAL ANTIRETROVIRAL DRUGS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Retail Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis
7.4. Others
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.4.3. Market Opportunity Analysis

8. GLOBAL ANTIRETROVIRAL DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.5.3. Market Opportunity Analysis
8.6. Global Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Class, Route of administration, Distribution Channel and Region, 2017 – 2023

9. NORTH AMERICA ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
  9.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
  9.1.3. Protease Inhibitors
  9.1.4. Integrate Inhibitors
  9.1.5. Fusion Inhibitors
  9.1.6. Chemokine Receptor Inhibitors
  9.1.7. Others
9.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.2.1. Parenteral
  9.2.2. Oral
9.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Retail Pharmacies
  9.3.2. Hospital Pharmacies
  9.3.3. Online Pharmacies
  9.3.4. Others
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
9.6. North America Antiretroviral Drugs Market Dynamics – Trends

10. EUROPE ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
  10.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
  10.1.3. Protease Inhibitors
  10.1.4. Integrate Inhibitors
  10.1.5. Fusion Inhibitors
  10.1.6. Chemokine Receptor Inhibitors
  10.1.7. Others
10.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Parenteral
  10.2.2. Oral
10.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Retail Pharmacies
  10.3.2. Hospital Pharmacies
  10.3.3. Online Pharmacies
  10.3.4. Others
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Germany
  10.4.2. UK
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Russia
  10.4.7. Poland
  10.4.8. Rest of Europe
10.5. Europe Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
10.6. Europe Antiretroviral Drugs Market Dynamics – Trends

11. ASIA-PACIFIC ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
  11.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
  11.1.3. Protease Inhibitors
  11.1.4. Integrate Inhibitors
  11.1.5. Fusion Inhibitors
  11.1.6. Chemokine Receptor Inhibitors
  11.1.7. Others
11.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Parenteral
  11.2.2. Oral
11.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Retail Pharmacies
  11.3.2. Hospital Pharmacies
  11.3.3. Online Pharmacies
  11.3.4. Others
11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  11.4.1. Japan
  11.4.2. China
  11.4.3. India
  11.4.4. ASEAN
  11.4.5. Australia & New Zealand
  11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
11.6. Europe Antiretroviral Drugs Market Dynamics – Trends

12. LATIN AMERICA ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
  12.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
  12.1.3. Protease Inhibitors
  12.1.4. Integrate Inhibitors
  12.1.5. Fusion Inhibitors
  12.1.6. Chemokine Receptor Inhibitors
  12.1.7. Others
12.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Parenteral
  12.2.2. Oral
12.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Retail Pharmacies
  12.3.2. Hospital Pharmacies
  12.3.3. Online Pharmacies
  12.3.4. Others
12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Argentina
  12.4.4. Venezuela
  12.4.5. Rest of Latin America
12.5. Latin America Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Antiretroviral Drugs Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
  13.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
  13.1.3. Protease Inhibitors
  13.1.4. Integrate Inhibitors
  13.1.5. Fusion Inhibitors
  13.1.6. Chemokine Receptor Inhibitors
  13.1.7. Others
13.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Parenteral
  13.2.2. Oral
13.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Retail Pharmacies
  13.3.2. Hospital Pharmacies
  13.3.3. Online Pharmacies
  13.3.4. Others
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Brazil
  13.4.2. Mexico
  13.4.3. Argentina
  13.4.4. Venezuela
  13.4.5. Rest of Latin America
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.5.1. Gulf Cooperation Council (GCC) Countries
  13.5.2. Israel
  13.5.3. South Africa
  13.5.4. Rest of MEA
13.6. MEA Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
13.7. MEA Antiretroviral Drugs Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Abbott Laboratories (U.S.)
  14.2.2. AstraZeneca plc (U.K.)
  14.2.3. Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S)
  14.2.4. Gilead Sciences (U.S.)
  14.2.5. GlaxoSmithKline Plc (U.K.)
  14.2.6. F. Hoffmann-La Roche AG (Switzerland)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS